Rare disease pharmacy solutions provider Orsini announced on Monday that it has been selected by ophthalmic pharmaceuticals and medical technology company Glaukos Corporation (NYSE:GKOS) as its single-source specialty pharmacy partner for Epioxa, a novel, groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease.

Approved by the FDA in October 2025, Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to reduce pain associated with removal of the epithelium, streamline the procedure and minimise recovery.

Keratoconus is an advancing eye disease that gradually thins the cornea and causes it to bulge outward into a cone shape, distorting patients' vision. Those affected by keratoconus may experience blurring and distorted vision, increased sensitivity to light and glare and frequent changes in eyeglass prescriptions, symptoms which progressively worsen over time. If left untreated, keratoconus can lead to loss of visual function and is one of the leading causes of corneal transplants in the United States.